Toward an integrative model of the spectrum of mood, behavioral and personality disorders based on fear and anger traits: II. Implications for neurobiology, genetics and psychopharmacological treatment.

[1]  H. Akiskal,et al.  The 5HTTLPR polymorphism of the serotonin transporter gene is associated with affective temperaments as measured by TEMPS-A. , 2006, Journal of affective disorders.

[2]  D. Theobald,et al.  An essential role for ΔFosB in the nucleus accumbens in morphine action , 2006, Nature Neuroscience.

[3]  E. Kandel,et al.  CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Kandel,et al.  stathmin, a Gene Enriched in the Amygdala, Controls Both Learned and Innate Fear , 2005, Cell.

[5]  A. Gamma,et al.  The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. , 2005, Journal of affective disorders.

[6]  M. Gratacós,et al.  Contribution of NTRK2 to the genetic susceptibility to anorexia nervosa, Harm avoidance and minimum body mass index , 2005, Molecular Psychiatry.

[7]  Vanessa Kazlauckas,et al.  Behavioral and cognitive profile of mice with high and low exploratory phenotypes , 2005, Behavioural Brain Research.

[8]  Jonathan D. Cohen,et al.  An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.

[9]  J. Calabrese,et al.  A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. , 2005, The American journal of psychiatry.

[10]  R. Ponnusamy,et al.  Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. , 2005, Learning & memory.

[11]  M. Alda,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. , 2005, Bipolar disorders.

[12]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[13]  P. Willner,et al.  Dopaminergic mechanism of antidepressant action in depressed patients. , 2005, Journal of affective disorders.

[14]  J. Mazziotta,et al.  Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression , 2005, Molecular Psychiatry.

[15]  Brien Riley,et al.  The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. , 2005, Archives of general psychiatry.

[16]  J. Calabrese,et al.  Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder , 2005, Acta psychiatrica Scandinavica. Supplementum.

[17]  Avshalom Caspi,et al.  Strategy for investigating interactions between measured genes and measured environments. , 2005, Archives of general psychiatry.

[18]  J. Linden,et al.  A Crucial Role for Forebrain Adenosine A2A Receptors in Amphetamine Sensitization , 2005, Neuropsychopharmacology.

[19]  E. Rüther,et al.  Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls , 2005, Psychiatry Research.

[20]  Mathias V. Schmidt,et al.  Stress, genes and the mechanism of programming the brain for later life , 2005, Neuroscience & Biobehavioral Reviews.

[21]  J. Kelsoe,et al.  Familiality of temperament in bipolar disorder: support for a genetic spectrum. , 2005, Journal of affective disorders.

[22]  F. Holsboer,et al.  Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression‐like behaviour: effects of chronic paroxetine treatment , 2005, Journal of neurochemistry.

[23]  H. Akiskal,et al.  The cyclothymic temperament in healthy controls and familially at risk individuals for mood disorder: endophenotype for genetic studies? , 2005, Journal of affective disorders.

[24]  H. Akiskal,et al.  Affective temperaments as measured by TEMPS-A in patients with bipolar I disorder and their first-degree relatives: a controlled study. , 2005, Journal of affective disorders.

[25]  E. Hollander,et al.  Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. , 2005, The American journal of psychiatry.

[26]  Diogo R Lara,et al.  A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. , 2005, The Journal of clinical psychiatry.

[27]  J. W. Aldridge,et al.  Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's , 2005, BMC Biology.

[28]  G. Piras,et al.  The psychogenetically selected Roman rat lines differ in the susceptibility to develop amphetamine sensitization , 2005, Behavioural Brain Research.

[29]  Peter B. Jones,et al.  Gender differences in incidence and age at onset of mania and bipolar disorder over a 35-year period in Camberwell, England. , 2005, The American journal of psychiatry.

[30]  T. Steimer,et al.  Inter-individual vs line/strain differences in psychogenetically selected Roman High-(RHA) and Low-(RLA) Avoidance rats: neuroendocrine and behavioural aspects , 2005, Neuroscience & Biobehavioral Reviews.

[31]  H Völzke,et al.  Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden , 2005, Molecular Psychiatry.

[32]  J. Salamone,et al.  Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. , 2005, Current opinion in pharmacology.

[33]  Shagufta Ahmad,et al.  Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids , 2005, Epilepsy Research.

[34]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[35]  M. Oscar-Berman,et al.  Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[36]  H. Covington,et al.  Long-term behavioral and neuronal cross-sensitization to amphetamine induced by repeated brief social defeat stress: Fos in the ventral tegmental area and amygdala , 2004, Neuroscience.

[37]  John H Krystal,et al.  Social supports and serotonin transporter gene moderate depression in maltreated children. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Feldon,et al.  Mesolimbic dopaminergic pathways in fear conditioning , 2004, Progress in Neurobiology.

[39]  J. Hennen,et al.  Axis II comorbidity of borderline personality disorder: description of 6‐year course and prediction to time‐to‐remission , 2004, Acta psychiatrica Scandinavica.

[40]  T. Bredy,et al.  Epigenetic Programming of Stress Responses through Variations in Maternal Care , 2004, Annals of the New York Academy of Sciences.

[41]  John Duncan,et al.  State Anxiety Modulation of the Amygdala Response to Unattended Threat-Related Stimuli , 2004, The Journal of Neuroscience.

[42]  J. Savitz,et al.  Genetic variants implicated in personality: A review of the more promising candidates , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[43]  F. Rachid,et al.  Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. , 2004, The Journal of clinical psychiatry.

[44]  R. Hen,et al.  Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice , 2004, Science.

[45]  D. Chapman,et al.  Adverse childhood experiences and the risk of depressive disorders in adulthood. , 2004, Journal of affective disorders.

[46]  Jonathan D. Cohen,et al.  Computational roles for dopamine in behavioural control , 2004, Nature.

[47]  R. Sprengel,et al.  Reduced aggression in AMPA‐type glutamate receptor GluR‐A subunit‐deficient mice , 2004, Genes, brain, and behavior.

[48]  R Plomin,et al.  Gene–environment interaction analysis of serotonin system markers with adolescent depression , 2004, Molecular Psychiatry.

[49]  B. Everitt,et al.  Direct Interactions between the Basolateral Amygdala and Nucleus Accumbens Core Underlie Cocaine-Seeking Behavior by Rats , 2004, The Journal of Neuroscience.

[50]  A. Bonci,et al.  The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference , 2004, Nature Neuroscience.

[51]  W. Nolen,et al.  Impact of stressful life events, familial loading and their interaction on the onset of mood disorders , 2004, British Journal of Psychiatry.

[52]  P. Celada,et al.  The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. , 2004, Journal of Psychiatry & Neuroscience.

[53]  J. D. McGaugh.  The amygdala modulates the consolidation of memories of emotionally arousing experiences. , 2004, Annual review of neuroscience.

[54]  M. Avanzi,et al.  Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease , 2004, Neurological Sciences.

[55]  I. Lyoo,et al.  Trait and state aspects of harm avoidance and its implication for treatment in major depressive disorder, dysthymic disorder, and depressive personality disorder , 2004, Psychiatry and clinical neurosciences.

[56]  C. Baldassano,et al.  The current understanding of lamotrigine as a mood stabilizer. , 2004, The Journal of clinical psychiatry.

[57]  B. McEwen,et al.  Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Burdick,et al.  Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. , 2004, The American journal of psychiatry.

[59]  K. Jamison,et al.  Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of psychiatry.

[60]  D. Charney,et al.  Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. , 2004, The American journal of psychiatry.

[61]  H. Anisman,et al.  Differential involvement of amygdaloid CRH system(s) in the salience and valence of the stimuli , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[62]  P. Sullivan,et al.  Temperament, childhood environment and psychopathology as risk factors for avoidant and borderline personality disorders , 2003, The Australian and New Zealand journal of psychiatry.

[63]  H. Lipp,et al.  Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice , 2003, Behavioural Brain Research.

[64]  H. Steiner,et al.  Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. , 2003, The Journal of clinical psychiatry.

[65]  F. Karayanidis,et al.  Disrupted sensory gating in pathological gambling , 2003, Biological Psychiatry.

[66]  M. Stacy,et al.  Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease , 2003, Neurology.

[67]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[68]  T. Suppes,et al.  Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. , 2003, The American journal of psychiatry.

[69]  P. Cowen,et al.  Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. , 2003, The American journal of psychiatry.

[70]  S. Pliszka.  Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder , 2003, CNS Spectrums.

[71]  A. Swann,et al.  Neuroreceptor mechanisms of aggression and its treatment. , 2003, The Journal of clinical psychiatry.

[72]  M. Geyer,et al.  Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system , 2003, Biological Psychiatry.

[73]  D. Souza,et al.  Allopurinol for the treatment of aggressive behaviour in patients with dementia , 2003, International clinical psychopharmacology.

[74]  C. Ledent,et al.  Low Ethanol Sensitivity and Increased Ethanol Consumption in Mice Lacking Adenosine A2A Receptors , 2002, The Journal of Neuroscience.

[75]  P. Leombruni,et al.  Temperament and character profile of eating disorders: a controlled study with the Temperament and Character Inventory. , 2002, The International journal of eating disorders.

[76]  M. Palkovits,et al.  Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study , 2002, Neuroendocrinology.

[77]  I. Hernádi,et al.  Iontophoresis of lithium antagonizes noradrenergic action on prefrontal neurons of the rat , 2002, Brain Research.

[78]  S. Starkstein,et al.  A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[79]  B. Fredholm,et al.  Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate , 2002, The European journal of neuroscience.

[80]  A. Tobeña,et al.  Enduring effects of environmental enrichment on novelty seeking, saccharin and ethanol intake in two rat lines (RHA/Verh and RLA/Verh) differing in incentive-seeking behavior , 2002, Pharmacology Biochemistry and Behavior.

[81]  R. Bressan,et al.  Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia , 2002, Schizophrenia Research.

[82]  F. Kugelberg,et al.  Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats. , 2002, Pharmacology & toxicology.

[83]  V. Sossi,et al.  PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. , 2002, The American journal of psychiatry.

[84]  C. Bowden.  Pharmacological Treatment of Bipolar Disorder , 2002 .

[85]  R D Spealman,et al.  Cocaine Administered into the Medial Prefrontal Cortex Reinstates Cocaine-Seeking Behavior by Increasing AMPA Receptor-Mediated Glutamate Transmission in the Nucleus Accumbens , 2002, The Journal of Neuroscience.

[86]  S. Strakowski,et al.  Human Response to Repeated Low-Dose d-Amphetamine: Evidence for Behavioral Enhancement and Tolerance , 2001, Neuropsychopharmacology.

[87]  William Perry,et al.  Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania , 2001, Biological Psychiatry.

[88]  J. Becker,et al.  Gender Differences in the Behavioral Responses to Cocaine and Amphetamine , 2001, Annals of the New York Academy of Sciences.

[89]  H. Akiskal,et al.  The contrasting influence of depressive and hyperthymic temperaments on psychometrically derived manic subtypes , 2001, Psychiatry Research.

[90]  M. Leboyer,et al.  Antidepressant-induced mania in bipolar patients: identification of risk factors. , 2001, The Journal of clinical psychiatry.

[91]  M. Bergström,et al.  D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study , 2001, European Neuropsychopharmacology.

[92]  P. D’Aquila,et al.  Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole. , 2001, European journal of pharmacology.

[93]  Yu-Shin Ding,et al.  Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain , 2001, The Journal of Neuroscience.

[94]  M. Frye,et al.  Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder , 2001, Biological Psychiatry.

[95]  A. Schatzberg.  New indications for antidepressants. , 2000, The Journal of clinical psychiatry.

[96]  A. Grace,et al.  The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. , 2000, Addiction.

[97]  J. Seibyl,et al.  Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.

[98]  Robert Freedman,et al.  The P50 auditory event–evoked potential in adult attention-deficit disorder: comparison with schizophrenia , 2000, Biological Psychiatry.

[99]  S. Kapur,et al.  A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.

[100]  P. D’Aquila,et al.  Chronic lithium chloride fails to prevent imipramine-induced sensitization to the dopamine D(2)-like receptor agonist quinpirole. , 2000, European journal of pharmacology.

[101]  J. Lépine,et al.  Normative data and factor structure of the Temperament and Character Inventory (TCI) in the French version , 2000, Psychiatry Research.

[102]  D. Souza,et al.  Allopurinol for refractory aggression and self-inflicted behaviour , 2000, Journal of psychopharmacology.

[103]  S. Rohrmann,et al.  Endocrine Responses after d-Fenfluramineand Ipsapirone Challenge: Further Support for Cloninger’s Tridimensional Model of Personality , 2000, Neuropsychobiology.

[104]  M. Low,et al.  Dopamine D4 Receptor-Knock-Out Mice Exhibit Reduced Exploration of Novel Stimuli , 1999, The Journal of Neuroscience.

[105]  Bernhard Lüscher,et al.  Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues , 1999, Nature Neuroscience.

[106]  H. Akiskal,et al.  The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. , 1999, The Journal of clinical psychiatry.

[107]  C. R. Cloninger,et al.  A New Conceptual Paradigm from Genetics and Psychobiology for the Science of Mental Health , 1999, The Australian and New Zealand journal of psychiatry.

[108]  Florian Holsboer,et al.  Behavioral, Physiological, and Neuroendocrine Stress Responses and Differential Sensitivity to Diazepam in Two Wistar Rat Lines Selectively Bred for High- and Low-Anxiety–Related Behavior , 1998, Neuropsychopharmacology.

[109]  C. Bowden,et al.  Bupropion slow-release response in depression: diagnosis and biochemistry , 1998, Biological Psychiatry.

[110]  M Freedman,et al.  Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[112]  M. Collu,et al.  Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. , 1997, European journal of pharmacology.

[113]  F. Lechin,et al.  Stress versus depression , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[114]  Stefan Gottschalk,et al.  Akathisia and Restless Legs , 1996 .

[115]  S Maccari,et al.  Stress-induced sensitization and glucocorticoids. I. Sensitization of dopamine-dependent locomotor effects of amphetamine and morphine depends on stress-induced corticosterone secretion , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[116]  C. Robert Cloninger,et al.  Temperament predicts clomipramine and desipramine response in major depression. , 1994, Journal of affective disorders.

[117]  C. R. Cloninger,et al.  A psychobiological model of temperament and character. , 1993, Archives of general psychiatry.

[118]  H. Akiskal,et al.  Further distinctions between manic-depressive illness (bipolar disorder) and primary depressive disorder (unipolar depression) , 1993, The American journal of psychiatry.

[119]  T. Joseph,et al.  Effect of antiepileptic drugs valproic acid, carbamazepine and ethosuccimide on exploratory behaviour in mice. , 1991, Indian journal of experimental biology.

[120]  S. Koslow,et al.  Lithium carbonate treatment of mania , 1988 .

[121]  E. Robins,et al.  Lithium carbonate treatment of mania. Cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. , 1987, Archives of general psychiatry.

[122]  Y. Lecrubier,et al.  Efficacy of clonidine in 24 patients with acute mania. , 1986, The American journal of psychiatry.

[123]  B. Yusta,et al.  Differential distribution of neurotransmitter amino acids from the limbic system of aggressive and non-aggressive bull strains , 1986, Pharmacology Biochemistry and Behavior.

[124]  J. Alpert,et al.  Neurophysiological studies of sensory gating in mania: comparison with schizophrenia. , 1983, Biological psychiatry.

[125]  D. Theobald,et al.  An essential role for DeltaFosB in the nucleus accumbens in morphine action. , 2006, Nature neuroscience.

[126]  P. Svenningsson,et al.  Adenosine and brain function. , 2005, International review of neurobiology.

[127]  M. Thase,et al.  Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. , 2005, Archives of general psychiatry.

[128]  E. Hollander,et al.  Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? , 2005, The American journal of psychiatry.

[129]  F. Holsboer,et al.  Alterations in Central Neuropeptide Expression, Release, and Receptor Binding in Rats Bred for High Anxiety: Critical Role of Vasopressin , 2004, Neuropsychopharmacology.

[130]  P. Sullivan,et al.  Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. , 2003, Comprehensive psychiatry.

[131]  J. Kelsoe.  Arguments for the genetic basis of the bipolar spectrum. , 2003, Journal of affective disorders.

[132]  C. Nemeroff,et al.  The role of GABA in the pathophysiology and treatment of anxiety disorders. , 2003, Psychopharmacology bulletin.

[133]  E. Hollander,et al.  Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders* , 2003, Neuropsychopharmacology.

[134]  C. Nemeroff,et al.  Pharmacology of valproate. , 2003, Psychopharmacology bulletin.

[135]  S. Tsai,et al.  Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.

[136]  G. Wiesbeck,et al.  Neuroendocrine responses to fenfluramine and its relationship to personality in alcoholism , 2001, Journal of Neural Transmission.

[137]  D. Kupfer,et al.  Stressful life events, bipolar disorder, and the "kindling model". , 2000, Journal of abnormal psychology.

[138]  C. Robert Cloninger,et al.  Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder. , 1998, Psychopharmacology bulletin.

[139]  D. S. Zahm,et al.  Is the caudomedial shell of the nucleus accumbens part of the extended amygdala? A consideration of connections. , 1998, Critical reviews in neurobiology.

[140]  M. Linnoila,et al.  A nonhuman primate model of excessive alcohol intake. Personality and neurobiological parallels of type I- and type II-like alcoholism. , 1997, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.

[141]  C. R. Cloninger,et al.  The temperament and character inventory (TCI) : a guide to its development and use , 1994 .

[142]  P. Cowen,et al.  Increased Positive versus Negative Affective Perception and Memory in Healthy Volunteers following Selective Serotonin and Norepinephrine Reuptake Inhibition , 2022 .